What is the appropriate evaluation and management of insomnia in a 69‑year‑old patient?

Management of Insomnia in a 69-Year-Old Patient

Start with cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, and only add pharmacotherapy through shared decision-making if CBT-I fails or is unavailable. 1

Initial Evaluation

Conduct a thorough clinical assessment focusing on:

• Sleep-specific history: Sleep habits, time to fall asleep vs. difficulty maintaining sleep (older adults more commonly report waking after sleep onset rather than initial insomnia), early morning awakening, total time in bed vs. actual sleep time 2
• Medication review: All prescription and over-the-counter drugs that may disrupt sleep including β-blockers, bronchodilators, corticosteroids, decongestants, diuretics, SSRIs/SNRIs, pseudoephedrine, caffeine-containing preparations, and nicotine products 2
• Medical comorbidities: Cardiac disease, COPD, CHF, pain from osteoarthritis/cancer/diabetes, nocturia from prostate enlargement, neurologic deficits from stroke or Parkinson's disease 2
• Psychiatric conditions: Depression and anxiety are common contributors 2
• Sleep diary: Have patient maintain for 2 weeks to document actual sleep patterns 2

Physical examination should be focused based on history findings. Laboratory tests and polysomnography are not routinely indicated unless history suggests sleep-related breathing disorders, periodic limb movements, or treatment-resistant insomnia 2.

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is the initial treatment of choice with strong evidence showing sustained benefits up to 2 years in older adults. 1, 2 This multimodal approach combines:

Core Components:

1. Sleep restriction/compression therapy:

   • Limit time in bed to match actual sleep time based on sleep diary
   • Example: If patient spends 8.5 hours in bed but sleeps only 5.5 hours, restrict bed time to 5.5-6 hours
   • Gradually increase by 15-20 minutes every 5 days as sleep efficiency improves 2

2. Stimulus control:

   • Use bedroom only for sleep and sex
   • Leave bedroom if unable to fall asleep within 15-20 minutes
   • Maintain consistent wake times regardless of sleep obtained
   • Avoid daytime napping (if necessary, limit to 30 minutes before 2 PM) 2

3. Sleep hygiene education:

   • Avoid caffeine, nicotine, and alcohol close to bedtime
   • No heavy exercise within 2 hours of bedtime
   • Optimize bedroom environment (temperature, noise, light)
   • Address pets or noisy bed partners 2

4. Cognitive restructuring: Address anxiety about sleep and unrealistic expectations about sleep needs in older adults 2

CBT-I can be delivered through individual/group therapy, telephone, web-based modules, or self-help books by trained clinicians 1.

Pharmacotherapy: Second-Line When CBT-I Insufficient

Use shared decision-making to discuss benefits, harms, and costs before adding medications. 1 This is a weak recommendation given low-quality evidence for long-term use.

Preferred Agents in Older Adults:

Start all medications at the lowest available dose due to increased sensitivity and reduced clearance in older adults 2.

• Nonbenzodiazepine receptor agonists (zolpidem, zaleplon, eszopiclone): Lower frequency and severity of adverse effects compared to older benzodiazepines, though still carry risks 2

• Melatonin receptor agonist (ramelteon): No demonstrated potential for abuse, motor impairment, or cognitive impairment—particularly favorable safety profile for older adults 2

• Prolonged-release melatonin: Indicated for this age group with high treatment safety 3

Agents to Avoid:

Do not use antihistamines, antidepressants (including trazodone), antipsychotics, or anticonvulsants off-label—risks outweigh benefits with no systematic evidence of effectiveness 2.

Benzodiazepines carry higher risk of adverse effects including falls, cognitive impairment, and dependence in older adults 2.

Critical Considerations for This Age Group:

• Older adults are at greater risk for adverse medication effects due to pharmacokinetic changes (reduced clearance) and pharmacodynamic differences (increased sensitivity to peak effects) 2

• Polypharmacy is common at age 69—carefully review all medications for drug-drug interactions and sleep-disrupting effects 2

• Combination therapy (CBT-I plus pharmacotherapy) may provide better short-term outcomes, but behavioral therapy provides superior long-term sustained benefit 2

• Treatment duration: Pharmacotherapy evidence supports only short-term use (≤4 weeks); CBT-I provides durable effects 1, 2

Common Pitfalls to Avoid:

• Assuming insomnia is a "normal part of aging"—it requires evaluation and treatment 4
• Prescribing medications without first attempting CBT-I 1
• Using long-acting benzodiazepines or medications with significant anticholinergic effects
• Failing to address underlying medical/psychiatric comorbidities that perpetuate insomnia 2
• Not reviewing and discontinuing sleep-disrupting medications when possible 2